Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.

Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, Sood AK.

Gynecol Oncol. 2019 Sep;154(3):524-530. doi: 10.1016/j.ygyno.2019.07.004. Epub 2019 Jul 25.

PMID:
31353053
2.

Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery.

Meyer LA, Shi Q, Lasala J, Iniesta MD, Lin HK, Nick AM, Williams L, Sun C, Wang XS, Lu KH, Ramirez PT.

Gynecol Oncol. 2019 Mar;152(3):501-508. doi: 10.1016/j.ygyno.2018.10.044.

PMID:
30876495
3.

Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.

Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK.

Obstet Gynecol. 2018 Sep;132(3):545-554. doi: 10.1097/AOG.0000000000002796.

4.

The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer.

Jalloul RJ, Nick AM, Munsell MF, Westin SN, Ramirez PT, Frumovitz M, Soliman PT.

J Gynecol Oncol. 2018 Sep;29(5):e68. doi: 10.3802/jgo.2018.29.e68. Epub 2018 May 4.

5.

Effect of an Enhanced Recovery After Surgery Program on Opioid Use and Patient-Reported Outcomes.

Meyer LA, Lasala J, Iniesta MD, Nick AM, Munsell MF, Shi Q, Wang XS, Cain KE, Lu KH, Ramirez PT.

Obstet Gynecol. 2018 Aug;132(2):281-290. doi: 10.1097/AOG.0000000000002735.

6.

Dual progestin therapy for fertility-sparing treatment of grade 2 endometrial adenocarcinoma.

Newtson AM, Pakish JB, Nick AM, Westin SN.

Gynecol Oncol Rep. 2017 Aug 8;21:117-118. doi: 10.1016/j.gore.2017.08.001. eCollection 2017 Aug.

7.

Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery.

Wang H, Li X, Volk DE, Lokesh GL, Elizondo-Riojas MA, Li L, Nick AM, Sood AK, Rosenblatt KP, Gorenstein DG.

Biotechniques. 2016 Nov 1;61(5):249-259. eCollection 2016.

8.

Platelets are not hyperreactive in patients with ovarian cancer.

Feng S, Kroll MH, Nick AM, Sood AK, Afshar-Kharghan V.

Platelets. 2016 Nov;27(7):716-718. Epub 2016 May 16.

9.

Precision Nanomedicine Using Dual PET and MR Temperature Imaging-Guided Photothermal Therapy.

Zhou M, Melancon M, Stafford RJ, Li J, Nick AM, Tian M, Sood AK, Li C.

J Nucl Med. 2016 Nov;57(11):1778-1783. Epub 2016 Jun 9.

10.

Quality of life after radical trachelectomy for early-stage cervical cancer: A 5-year prospective evaluation.

Fleming ND, Ramirez PT, Soliman PT, Schmeler KM, Chisholm GB, Nick AM, Westin SN, Frumovitz M.

Gynecol Oncol. 2016 Dec;143(3):596-603. doi: 10.1016/j.ygyno.2016.10.012. Epub 2016 Oct 11.

11.

The DISINFECT Initiative: Decreasing the Incidence of Surgical INFECTions in Gynecologic Oncology.

Taylor JS, Marten CA, Munsell MF, Sun CC, Potts KA, Burzawa JK, Nick AM, Meyer LA, Myers K, Bodurka DC, Aloia TA, Levenback CF, Lairson DR, Schmeler KM.

Ann Surg Oncol. 2017 Feb;24(2):362-368. doi: 10.1245/s10434-016-5517-4. Epub 2016 Aug 29.

12.

What Is the Real Rate of Surgical Site Infection?

Taylor JS, Marten CA, Potts KA, Cloutier LM, Cain KE, Fenton SL, Tatum TN, James DA, Myers KN, Hubbs CA, Burzawa JK, Vachhani S, Nick AM, Meyer LA, Graviss LS, Ware KM, Park AK, Aloia TA, Bodurka DC, Levenback CF, Schmeler KM.

J Oncol Pract. 2016 Oct;12(10):e878-e883.

13.

Lipid profile of platelets and platelet-derived microparticles in ovarian cancer.

Hu Q, Wang M, Cho MS, Wang C, Nick AM, Thiagarajan P, Aung FM, Han X, Sood AK, Afshar-Kharghan V.

BBA Clin. 2016 Jun 30;6:76-81. doi: 10.1016/j.bbacli.2016.06.003. eCollection 2016 Dec.

14.

Role of cervical cytology in surveillance after radical trachelectomy for cervical cancer.

Brown AJ, Shah JS, Fleming ND, Nick AM, Soliman PT, Chisholm GB, Schmeler KM, Ramirez PT, Frumovitz M.

Gynecol Oncol. 2016 Aug;142(2):283-5. doi: 10.1016/j.ygyno.2016.05.030. Epub 2016 Jun 6.

15.

FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.

Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK.

J Clin Invest. 2016 May 2;126(5):1885-96. doi: 10.1172/JCI85086. Epub 2016 Apr 11.

16.

Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.

Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn LM, Ng CS, Piha-Paul SA, Janku F, Subbiah V, Tsimberidou A, Karp D, Meric-Bernstam F, Lu KH, Naing A.

Cancer Chemother Pharmacol. 2016 May;77(5):973-7. doi: 10.1007/s00280-016-3009-7. Epub 2016 Mar 24.

17.

Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.

Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK.

Mol Cancer Ther. 2016 Jun;15(6):1344-52. doi: 10.1158/1535-7163.MCT-15-0144. Epub 2016 Mar 23.

18.

Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.

Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA.

Gynecol Oncol. 2016 May;141(2):260-263. doi: 10.1016/j.ygyno.2016.03.010. Epub 2016 Mar 11.

19.

A call for new standard of care in perioperative gynecologic oncology practice: Impact of enhanced recovery after surgery (ERAS) programs.

Miralpeix E, Nick AM, Meyer LA, Cata J, Lasala J, Mena GE, Gottumukkala V, Iniesta-Donate M, Salvo G, Ramirez PT.

Gynecol Oncol. 2016 May;141(2):371-378. doi: 10.1016/j.ygyno.2016.02.019. Epub 2016 Mar 9. Review.

20.

Carcinoma of the Bartholin Gland: A Review of 33 Cases.

Bhalwal AB, Nick AM, Dos Reis R, Chen CL, Munsell MF, Ramalingam P, Salcedo MP, Ramirez PT, Sood AK, Schmeler KM.

Int J Gynecol Cancer. 2016 May;26(4):785-9. doi: 10.1097/IGC.0000000000000656.

21.

Role of Increased n-acetylaspartate Levels in Cancer.

Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK.

J Natl Cancer Inst. 2016 Jan 26;108(6):djv426. doi: 10.1093/jnci/djv426.

22.

Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer.

Wang R, Stone RL, Kaelber JT, Rochat RH, Nick AM, Vijayan KV, Afshar-Kharghan V, Schmid MF, Dong JF, Sood AK, Chiu W.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14266-71. doi: 10.1073/pnas.1518628112. Epub 2015 Nov 2.

23.

Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases.

Callegaro-Filho D, Gershenson DM, Nick AM, Munsell MF, Ramirez PT, Eifel PJ, Euscher ED, Marques RM, Nicolau SM, Schmeler KM.

Gynecol Oncol. 2016 Jan;140(1):53-7. doi: 10.1016/j.ygyno.2015.11.004. Epub 2015 Nov 4.

24.

Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.

Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK.

Mol Cancer Ther. 2015 Dec;14(12):2677-86. doi: 10.1158/1535-7163.MCT-14-0630. Epub 2015 Oct 29.

25.

Erythropoietin Stimulates Tumor Growth via EphB4.

Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Peña GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK.

Cancer Cell. 2015 Nov 9;28(5):610-622. doi: 10.1016/j.ccell.2015.09.008. Epub 2015 Oct 17.

26.

Fundamental Principles of Cancer Biology: Does it have relevance to the perioperative period?

Jiang L, Nick AM, Sood AK.

Curr Anesthesiol Rep. 2015 Sep;5(3):250-256.

27.

Impact of Lymph Node Ratio and Adjuvant Therapy in Node-Positive Endometrioid Endometrial Cancer.

Fleming ND, Soliman PT, Westin SN, dos Reis R, Munsell M, Klopp AH, Frumovitz M, Nick AM, Schmeler K, Ramirez PT.

Int J Gynecol Cancer. 2015 Oct;25(8):1437-44. doi: 10.1097/IGC.0000000000000510.

28.

Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer.

Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AK.

Cancer. 2015 Oct 1;121(19):3444-51. doi: 10.1002/cncr.29392. Epub 2015 Aug 24.

29.

Improvement in quality of life after robotic surgery results in patient satisfaction.

Arms RG 3rd, Sun CC, Burzawa JK, Fleming ND, Nick AM, Rallapalli V, Westin SN, Meyer LA, Ramirez PT, Soliman PT.

Gynecol Oncol. 2015 Sep;138(3):727-30. doi: 10.1016/j.ygyno.2015.07.013. Epub 2015 Jul 18.

30.

Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care.

Gómez-Hidalgo NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, Ramirez PT.

Gynecol Oncol. 2015 Jun;137(3):553-8. doi: 10.1016/j.ygyno.2015.03.049. Epub 2015 Mar 28. Review.

31.

A framework for a personalized surgical approach to ovarian cancer.

Nick AM, Coleman RL, Ramirez PT, Sood AK.

Nat Rev Clin Oncol. 2015 Apr;12(4):239-45. doi: 10.1038/nrclinonc.2015.26. Epub 2015 Feb 24. Review.

32.

Perioperative trajectory of patient reported symptoms: a pilot study in gynecologic oncology patients.

Meyer LA, Nick AM, Shi Q, Wang XS, Williams L, Brock T, Iniesta MD, Rangel K, Lu KH, Ramirez PT.

Gynecol Oncol. 2015 Mar;136(3):440-5. doi: 10.1016/j.ygyno.2015.01.547. Epub 2015 Jan 31.

33.

Differential platelet levels affect response to taxane-based therapy in ovarian cancer.

Bottsford-Miller J, Choi HJ, Dalton HJ, Stone RL, Cho MS, Haemmerle M, Nick AM, Pradeep S, Zand B, Previs RA, Pecot CV, Crane EK, Hu W, Lutgendorf SK, Afshar-Kharghan V, Sood AK.

Clin Cancer Res. 2015 Feb 1;21(3):602-10. doi: 10.1158/1078-0432.CCR-14-0870. Epub 2014 Dec 3.

34.

Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer.

Fleming ND, Frumovitz M, Schmeler KM, dos Reis R, Munsell MF, Eifel PJ, Soliman PT, Nick AM, Westin SN, Ramirez PT.

Gynecol Oncol. 2015 Jan;136(1):48-53. doi: 10.1016/j.ygyno.2014.11.010. Epub 2014 Nov 18.

35.

Position-related injury is uncommon in robotic gynecologic surgery.

Ulm MA, Fleming ND, Rallapali V, Munsell MF, Ramirez PT, Westin SN, Nick AM, Schmeler KM, Soliman PT.

Gynecol Oncol. 2014 Dec;135(3):534-8. doi: 10.1016/j.ygyno.2014.10.016. Epub 2014 Oct 23.

36.

Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence.

Carroll A, Ramirez PT, Westin SN, Soliman PT, Munsell MF, Nick AM, Schmeler KM, Klopp AH, Fleming ND.

Gynecol Oncol. 2014 Dec;135(3):455-61. doi: 10.1016/j.ygyno.2014.10.022. Epub 2014 Oct 28.

37.

Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.

Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK.

Clin Cancer Res. 2015 Jan 15;21(2):448-59. doi: 10.1158/1078-0432.CCR-14-1578. Epub 2014 Nov 21.

38.

Hematogenous metastasis of ovarian cancer: rethinking mode of spread.

Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK.

Cancer Cell. 2014 Jul 14;26(1):77-91. doi: 10.1016/j.ccr.2014.05.002.

39.

Minimally invasive surgery for endometrial cancer: does operative start time impact surgical and oncologic outcomes?

Slaughter KN, Frumovitz M, Schmeler KM, Nick AM, Fleming ND, dos Reis R, Munsell MF, Westin SN, Soliman PT, Ramirez PT.

Gynecol Oncol. 2014 Aug;134(2):248-52. doi: 10.1016/j.ygyno.2014.06.007. Epub 2014 Jun 16.

40.

Conversion from robotic surgery to laparotomy: a case-control study evaluating risk factors for conversion.

Jones N, Fleming ND, Nick AM, Munsell MF, Rallapalli V, Westin SN, Meyer LA, Schmeler KM, Ramirez PT, Soliman PT.

Gynecol Oncol. 2014 Aug;134(2):238-42. doi: 10.1016/j.ygyno.2014.06.008. Epub 2014 Jun 14.

41.

Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer.

Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AK.

Clin Cancer Res. 2014 Jun 15;20(12):3280-8. doi: 10.1158/1078-0432.CCR-14-0445. Epub 2014 Apr 22.

42.

Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.

Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, Lutgendorf S, Sood AK.

Cancer Biol Ther. 2014 Jul;15(7):919-29. doi: 10.4161/cbt.28882. Epub 2014 Apr 23.

43.

Notch3 pathway alterations in ovarian cancer.

Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK.

Cancer Res. 2014 Jun 15;74(12):3282-93. doi: 10.1158/0008-5472.CAN-13-2066. Epub 2014 Apr 17.

44.

Sustained complete response after maintenance therapy with topotecan and erlotinib for recurrent cervical cancer with distant metastases.

Callegaro-Filho D, Kavanagh JJ, Nick AM, Ramirez PT, Schmeler KM.

Case Rep Oncol. 2014 Jan 31;7(1):97-101. doi: 10.1159/000358916. eCollection 2014 Jan.

45.

Successful incorporation of robotic surgery into gynecologic oncology fellowship training.

Soliman PT, Iglesias D, Munsell MF, Frumovitz M, Westin SN, Nick AM, Schmeler KM, Ramirez PT.

Gynecol Oncol. 2013 Dec;131(3):730-3. doi: 10.1016/j.ygyno.2013.08.039. Epub 2013 Sep 19.

46.

Impact of cardiovascular comorbidity on ovarian cancer mortality.

Shinn EH, Lenihan DJ, Urbauer DL, Basen-Engquist KM, Valentine A, Palmero L, Woods ML, Patel P, Nick AM, Shahzad MM, Stone RL, Golden A, Atkinson E, Lutgendorf SK, Sood AK.

Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2102-9. doi: 10.1158/1055-9965.EPI-13-0625. Epub 2013 Sep 17.

47.

Incidence of trocar site herniation following robotic gynecologic surgery.

Clark LH, Soliman PT, Odetto D, Munsell MF, Schmeler KM, Fleming N, Westin SN, Nick AM, Ramirez PT.

Gynecol Oncol. 2013 Nov;131(2):400-3. doi: 10.1016/j.ygyno.2013.08.021. Epub 2013 Aug 27.

48.

Venous thromboembolic events in minimally invasive gynecologic surgery.

Ramirez PT, Nick AM, Frumovitz M, Schmeler KM.

J Minim Invasive Gynecol. 2013 Nov-Dec;20(6):766-9. doi: 10.1016/j.jmig.2013.06.001. Epub 2013 Jul 11. Review.

49.

Postoperative outcomes after continent versus incontinent urinary diversion at the time of pelvic exenteration for gynecologic malignancies.

Urh A, Soliman PT, Schmeler KM, Westin S, Frumovitz M, Nick AM, Fellman B, Urbauer DL, Ramirez PT.

Gynecol Oncol. 2013 Jun;129(3):580-5. doi: 10.1016/j.ygyno.2013.02.024. Epub 2013 Feb 26.

50.

Src activation by β-adrenoreceptors is a key switch for tumour metastasis.

Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK.

Nat Commun. 2013;4:1403. doi: 10.1038/ncomms2413. Erratum in: Nat Commun. 2013;4:1932. Shazhad, Mian M K [corrected to Shahzad, Mian M K].

Supplemental Content

Support Center